Effect of Cyclosporine in a Murine Model of Experimental Colitis
- 92 Downloads
The use of immunosuppressive therapy may be associated with significant toxicity. The aim of this study was to investigate the effect of cyclosporine A (CsA) in murine model of experimental colitis. Experimental colitis was induced in NMRI mice using an enema of 0.2% solution of dinitrofluorobenzene, combined with skin sensitization. After inducing colitis, experimental groups of animals were treated with CsA (1, 3, 5, 10, 25, 50 mg/kg/day) intraperitoneally (i.p.) or intracolonically (i.c.), and control groups were treated with phosphate-buffered saline intraperitoneally or intracolonically, respectively. Colonic inflammatory changes were assessed using a histopathologic score of 0–30, and pooled whole blood samples were processed with monoclonal antibodies for cyclosporine concentration. In addition, two groups of animals with experimental colitis were treated intraperitoneally or intracolonically with 3 mg/kg/day of CsA, and the colons were also taken for immunohistochemistry for CD25. CsA diminished the extent of colitis in groups treated with 3, 5, 10, or 25 mg/kg intraperitoneally or intracolonically, and in groups treated with 1 and 50 mg/kg intracolonically (P < 0.05). The effect of intracolonic application of CsA was not related to whole blood cyclosporine concentrations. In addition, the effect of CsA at 3 mg/kg, applied intraperitoneally or intracolonically was, in part, expressed in decreasing the numbers of CD25+ cells within colonic mucosa/submucosa (P < 0.05). In conclusions, the results of this study indicate the possibility of intracolonic application of cyclosporine in order to widen the therapeutic window for effective, but possibly toxic drug, such as cyclosporine.
Unable to display preview. Download preview PDF.
- 5.Strober W, Ehrhardt RO, Ludviksson BR: Inflammatory bowel diseases: A breakdown of central and peripheral immunological homeostasis. In Inhibition and Modulation of gastrointestinal inflammation. Falk Symposium 104. A Stallmach, M Zeitz, W Strober, TT MacDonald, H Lochs (eds). Dordrecht, Kluwer Academic Publishers, 1998, pp 97–110Google Scholar
- 11.Velja?a M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglieta A: BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. JPET 272:417–422, 1995Google Scholar
- 12.Dawson-Saunders B, Trapp RG: Basic and Clinical Biostatistics. London, Prentice-Hall, 1994Google Scholar
- 16.Elson CO: Experimental models of intestinal inflammation. New insights into mechanisms of mucosal homeostasis: In PL Ogra, J Mestecky, ME Lamm, W Strober, J Bienenstock, JR McGhee (eds). Mucosal Immunology. San Diego, Academic Press, 1999, pp 1007–1024Google Scholar
- 18.Higa A, McKnight GW, Wallace JL: Attenuation of epithelial injury in acute experimental colitis by immunomodulators 239:171–176, 1993Google Scholar
- 21.Braunstein J, Autschbach F, Sido B, Nebl G, Schroeder A, Samstag Y, Meuer SC: Insensitivity towards inhibition by cyclosporine A, rapamycin and tacrolimus in human intestinal lamina propria T-lymphocytes. In Inhibition and Modulation of Gastrointestinal Inflammation. Falk Symposium 104. A Stallmach, M Zeitz, W Strober, TT MacDonald, H Lochs (eds). Dordrecht, Kluwer Academic Publishers, 1998, pp 97–110Google Scholar
- 23.Feagan BG, McDonald JWD, Rochon J, Laupacis A, Fedorak RN, Kinnear D, Saibil F, Groll A, Archambault A, Gillies R, Valberg B, Irvine J, for Canadian Crohn's Relapse Prevention Trial Investigators: Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 330:1846–1851, 1994PubMedGoogle Scholar
- 24.Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Bowel Dis 1:48–63, 1995Google Scholar
- 30.Brynskow J: Cyclosporine/Tacrolimus in Crohn's disease: acute and chronic. Falk symposium 119. Immunosuppression in inflammatory bowel disease—standards—new developments—future trends. Abstract Book, 2000, p 38Google Scholar